Drugs / 15N2-tofacitinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03103412 | May → Nov 2017 | ulcerative colitis | Theravance Biopharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 15N2-tofacitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03103412 ↗ |
| Route | Oral | “15N2-tofacitinib orally single dose” NCT03103412 ↗ |